Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JNGHFDrugs in Pipeline
133
Phase 3 Programs
71
Upcoming Catalysts
18
Next Catalyst
This month
Market Overview
Stock performance and key metrics
18 upcoming, 2 past
HRS-4357 injection
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Carboplatin
Lung Neoplasms
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Metastatic Pancreatic Cancer
Almonertinib
Non-small Cell Lung Cancer
Capecitabine tablets
Breast Cancer
camrelizumab； famitinib malate
Cervical Cancer
Noiiglutide Injection
Type 2 Diabetes
Propofol
Sedation
Pyrotinib in combination with Capecitabine.
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Fluzoparib capsules
Ovarian Cancer
pyrotinib
Non Small Cell Lung
SHR0302
Rheumatoid Arthritis
Paclitaxel Injection
Ovarian Cancer
Remimazolam Tosilate
Sedation
SHR8028 eye drops
Dry Eye Disease
SHR-A1811 for Injection
Early-stage or Locally Advanced HER2-positive Breast Cancer
SHR-A1811
Advanced Non-small Cell Lung Cancer
SHR-1209
Primary Hypercholesterolemia
INS068 injection
Type 2 Diabetes
Camrelizumab Plus Chemotherapy
Triple Negative Breast Cancer
SHR-A1811 Injection
Advanced Gastric Cancer
Fuzuloparib , Abiraterone acetate and Prednisone
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel
Non-squamous NSCLC
SHR-A1811 Injection ； Pertuzumab Injection
HER2-PositiveRecurrent or Metastatic Breast Cancer
68Ga-DOTATOC
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Apatinib Mesylate
Gastric Cancer
paclitaxel
Advanced Esophageal Cancer
Rezvilutamide Tablets
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
SHR6390
Advanced Breast Cancer
Famitinib
Colorectal Cancer Metastatic
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Advanced Pancreatic Cancer
HR17031 injection
Adult Patients With Type 2 Diabetes
HRS-8427
Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
SHR0410 Injection
Pain
SHR3680
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
SHR8554 Injection
Pain
Hetrombopag Olamine
Idiopathic Thrombocytopenic Purpura
SHR4640 dose1
Gout
Hetrombopag Olamine+Standard Therapy
Severe Aplastic Anemia
Herombopag tablets
Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Non-Small Cell Lung Cancer With HER2- Mutations
SHR8058 eye drops
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
SHR4640
Gout
Drug: Pegylated rhG-CSF: 100µg/kg
Breast Cancer
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Breast Cancer
KN046
Advanced Pancreatic Ductal Adenocarcinoma
FRSW117
Severe Hemophilia A
Irinotecan
Esophageal Carcinoma
SHR-1210
Gastric Cancer
Sorafenib
Locally Advanced or Metastatic and Unresectable HCC
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin
Non-Small-Cell Lung Cancer
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Rivoceranib (Apatinib)
Hepatocellular Carcinoma (HCC)
Camrelizumab
Solid Tumor
BP102, paclitaxel, carboplatin
Non-small Cell Lung Cancer(NSCLC)
Paracetamol injection
Post-operative Analgesia
SHR7280 tablets
Female Subjects Undergoing COH in ART to Prevent Early Ovulation
Remimazolam Tosilate for injection
Operative Sedation of Pediatric
SHR7280；Ganirelix Acetate Injection simulant
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
TACE+Camrelizumab+Apatinib mesylate
Hepatocellular Carcinoma
SHR2554; Chidamide analog tablets
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Apatinib
Carcinoma, Hepatocellular
X0002 Spray
KNEE OSTEOARTHRITIS
Morphine
Pain
JSKN003
Advanced Solid Tumor
Irinotecan liposome、5-Fluorouracil、Leucovorin
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Propofol Medium and Long Chain Fat Emulsion Injection
Sedation in the ICU
Capecitabine
Gastric Cancer
Insulin Glargine
Type 2 Diabetes Mellitus
Propofol Injection.
Local Anesthesia Assisted Sedation
SHR0302 Tablets
Non-segmental Vitiligo
Insulin Degludec
Type 2 Diabetes
APL-1202 treatment
Non-muscle Invasive Bladder Cancer
RSS0343 Tabella
Adolescent Asthma
Fluzoparib
Small Cell Lung Cancer
SHR-1020
Recurrent or Metastatic Cervical Cancer
KN026 combination
HER2-positive Solid Tumors
mFOLFIRINOX
Advanced Pancreatic Cancer
benzbromarone
Hyperuricemia
JSKN016
Inoperable Locally Advanced HER2-Negative Breast Cancer
HRG2010(I)
Parkinson's Disease
SHR2554/CHOP
Peripheral T-cell Lymphoma
SP2086(50 mg q.d.)/Metformin
Type 2 Diabetes
KN019, 5mg/kg
Rheumatoid Arthritis
HR18042
Moderate to Severe Acute Pain
KN026 10 mg/kg QW
Gastric/Gastroesophageal Junction Cancer
Camrelizumab、Rivoceranib
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Nab-paclitaxel
Triple-negative Breast Cancer
HRS-4508 tablet
Solid Tumor
Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets
Metastatic Castration Resistant Prostate Cancer
Sunitinib
Renal Cell Cancer
SHR-1701
Pancreatic Cancer
SHR117887
Type 2 Diabetes
HRS-8364 Tablet
Solid Tumor
HR021618
Pain After Abdominal Surgery
HS-10375
Advanced or Metastatic NSCLC
Adebrelimab
Advanced KRAS G12D Mutant Solid Tumors
SHR-1314
Moderate-to-severe Chronic Plaque Psoriasis
FOLFOX4
Advanced Primary Liver Cancer
HS-20004
Diabetes Mellitus, Type 2
HR020602 injection
Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
SS109
Male
HS-10365 capsules
Nonsmall Cell Lung Cancer
Pegylated rhG-CSF 100μg/kg
Breast Cancer
HR19042 Capsules
Autoimmune Hepatitis
HRS-9190
Neuromuscular Blockade
SHR0302Base gel
Vitiligo
Abiraterone Acetate Tablets (I)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
HRS-6209 in Combination with Fulvestrant
Advanced Unresectable or Metastatic Breast Cancer
HRS-1167 tablets
Prostate Cancer
HRS-4642
Advanced Solid Tumors
HRS4800 tablets
Pain
HS-20094
Type 2 Diabetes
SHR7280
Endometriosis
SHR-A1904
Advanced Solid Tumors
50 mg SP2086
Type 2 Diabetes
SHR-1703
Asthma With Eosinophilic Phenotype
HRS-6209 Capsules
Breast Cancer
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
Lung Cancer
HRS-6768
Advanced Solid Tumors
SHR- A1811
Gynaecological Malignancies
HRS-5041 tablets
Prostate Cancer
HRS-6213
Patients With Solid Tumors
SHR2554; SHR-A2102
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Fluzoparib+Apatinib
Relapsed Ovarian Cancer
FH-006
Malignant Solid Tumor
SHR 1210+apatinib
Hepatocellular Carcinoma
Meropenem
Hospital-acquired Bacterial Pneumonia (HABP)
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
Advanced Non-small Cell Lung Cancer
SHR-3167
Type 2 Diabetes
SHR-A1811 combined with Pyrotinib.
HER2-expressing Advanced Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HRS-4357 injection | Phase 3 | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | - | - |
Carboplatin | Phase 3 | Lung Neoplasms | - | - |
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Metastatic Pancreatic Cancer | - | - |
Almonertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
Capecitabine tablets | Phase 3 | Breast Cancer | - | - |
camrelizumab； famitinib malate | Phase 3 | Cervical Cancer | - | - |
Noiiglutide Injection | Phase 3 | Type 2 Diabetes | - | - |
Propofol | Phase 3 | Sedation | - | - |
Pyrotinib in combination with Capecitabine. | Phase 3 | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | - | - |
Fluzoparib capsules | Phase 3 | Ovarian Cancer | - | - |
pyrotinib | Phase 3 | Non Small Cell Lung | - | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - | - |
Paclitaxel Injection | Phase 3 | Ovarian Cancer | - | - |
Remimazolam Tosilate | Phase 3 | Sedation | - | - |
SHR8028 eye drops | Phase 3 | Dry Eye Disease | - | - |
SHR-A1811 for Injection | Phase 3 | Early-stage or Locally Advanced HER2-positive Breast Cancer | - | - |
SHR-A1811 | Phase 3 | Advanced Non-small Cell Lung Cancer | - | - |
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - | - |
INS068 injection | Phase 3 | Type 2 Diabetes | - | - |
Camrelizumab Plus Chemotherapy | Phase 3 | Triple Negative Breast Cancer | - | - |
SHR-A1811 Injection | Phase 3 | Advanced Gastric Cancer | - | - |
Fuzuloparib , Abiraterone acetate and Prednisone | Phase 3 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
Docetaxel | Phase 3 | Non-squamous NSCLC | - | - |
SHR-A1811 Injection ； Pertuzumab Injection | Phase 3 | HER2-PositiveRecurrent or Metastatic Breast Cancer | - | - |
68Ga-DOTATOC | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - | - |
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan | Phase 3 | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | - | - |
Apatinib Mesylate | Phase 3 | Gastric Cancer | - | - |
paclitaxel | Phase 3 | Advanced Esophageal Cancer | - | - |
Rezvilutamide Tablets | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | - | - |
SHR6390 | Phase 3 | Advanced Breast Cancer | - | - |
Famitinib | Phase 3 | Colorectal Cancer Metastatic | - | - |
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Advanced Pancreatic Cancer | - | - |
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes | - | - |
HRS-8427 | Phase 3 | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | - | - |
SHR0410 Injection | Phase 3 | Pain | - | - |
SHR3680 | Phase 3 | Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | - | - |
SHR8554 Injection | Phase 3 | Pain | - | - |
Hetrombopag Olamine | Phase 3 | Idiopathic Thrombocytopenic Purpura | - | - |
SHR4640 dose1 | Phase 3 | Gout | - | - |
Hetrombopag Olamine+Standard Therapy | Phase 3 | Severe Aplastic Anemia | - | - |
Herombopag tablets | Phase 3 | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | - | - |
Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin | Phase 3 | Non-Small Cell Lung Cancer With HER2- Mutations | - | - |
SHR8058 eye drops | Phase 3 | Treatment of Dry Eye Disease With Meibomian Gland Dysfunction | - | - |
SHR4640 | Phase 3 | Gout | - | - |
Drug: Pegylated rhG-CSF: 100µg/kg | Phase 3 | Breast Cancer | - | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - | - |
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel | Phase 3 | Breast Cancer | - | - |
KN046 | Phase 3 | Advanced Pancreatic Ductal Adenocarcinoma | - | - |
FRSW117 | Phase 3 | Severe Hemophilia A | - | - |
Irinotecan | Phase 3 | Esophageal Carcinoma | - | - |
SHR-1210 | Phase 3 | Gastric Cancer | - | - |
Sorafenib | Phase 3 | Locally Advanced or Metastatic and Unresectable HCC | - | - |
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - | - |
Rivoceranib (Apatinib) | Phase 3 | Hepatocellular Carcinoma (HCC) | - | - |
Camrelizumab | Phase 3 | Solid Tumor | - | - |
BP102, paclitaxel, carboplatin | Phase 3 | Non-small Cell Lung Cancer(NSCLC) | - | - |
Paracetamol injection | Phase 3 | Post-operative Analgesia | - | - |
SHR7280 tablets | Phase 3 | Female Subjects Undergoing COH in ART to Prevent Early Ovulation | - | - |
Remimazolam Tosilate for injection | Phase 3 | Operative Sedation of Pediatric | - | - |
SHR7280；Ganirelix Acetate Injection simulant | Phase 3 | Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation | - | - |
TACE+Camrelizumab+Apatinib mesylate | Phase 3 | Hepatocellular Carcinoma | - | - |
SHR2554; Chidamide analog tablets | Phase 3 | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | - | - |
Apatinib | Phase 3 | Carcinoma, Hepatocellular | - | - |
X0002 Spray | Phase 3 | KNEE OSTEOARTHRITIS | - | - |
Morphine | Phase 3 | Pain | - | - |
JSKN003 | Phase 3 | Advanced Solid Tumor | - | - |
Irinotecan liposome、5-Fluorouracil、Leucovorin | Phase 3 | Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy | - | - |
Propofol Medium and Long Chain Fat Emulsion Injection | Phase 3 | Sedation in the ICU | - | - |
Capecitabine | Phase 3 | Gastric Cancer | - | - |
Insulin Glargine | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Propofol Injection. | Phase 2 | Local Anesthesia Assisted Sedation | - | - |
SHR0302 Tablets | Phase 2 | Non-segmental Vitiligo | - | - |
Insulin Degludec | Phase 2 | Type 2 Diabetes | - | - |
APL-1202 treatment | Phase 2 | Non-muscle Invasive Bladder Cancer | - | - |
RSS0343 Tabella | Phase 2 | Adolescent Asthma | - | - |
Fluzoparib | Phase 2 | Small Cell Lung Cancer | - | - |
SHR-1020 | Phase 2 | Recurrent or Metastatic Cervical Cancer | - | - |
KN026 combination | Phase 2 | HER2-positive Solid Tumors | - | - |
mFOLFIRINOX | Phase 2 | Advanced Pancreatic Cancer | - | - |
benzbromarone | Phase 2 | Hyperuricemia | - | - |
JSKN016 | Phase 2 | Inoperable Locally Advanced HER2-Negative Breast Cancer | - | - |
HRG2010(I) | Phase 2 | Parkinson's Disease | - | - |
SHR2554/CHOP | Phase 2 | Peripheral T-cell Lymphoma | - | - |
SP2086(50 mg q.d.)/Metformin | Phase 2 | Type 2 Diabetes | - | - |
KN019, 5mg/kg | Phase 2 | Rheumatoid Arthritis | - | - |
HR18042 | Phase 2 | Moderate to Severe Acute Pain | - | - |
KN026 10 mg/kg QW | Phase 2 | Gastric/Gastroesophageal Junction Cancer | - | - |
Camrelizumab、Rivoceranib | Phase 2 | Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | - | - |
Nab-paclitaxel | Phase 2 | Triple-negative Breast Cancer | - | - |
HRS-4508 tablet | Phase 2 | Solid Tumor | - | - |
Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets | Phase 2 | Metastatic Castration Resistant Prostate Cancer | - | - |
Sunitinib | Phase 2 | Renal Cell Cancer | - | - |
SHR-1701 | Phase 2 | Pancreatic Cancer | - | - |
SHR117887 | Phase 2 | Type 2 Diabetes | - | - |
HRS-8364 Tablet | Phase 2 | Solid Tumor | - | - |
HR021618 | Phase 2 | Pain After Abdominal Surgery | - | - |
HS-10375 | Phase 2 | Advanced or Metastatic NSCLC | - | - |
Adebrelimab | Phase 2 | Advanced KRAS G12D Mutant Solid Tumors | - | - |
SHR-1314 | Phase 2 | Moderate-to-severe Chronic Plaque Psoriasis | - | - |
FOLFOX4 | Phase 2 | Advanced Primary Liver Cancer | - | - |
HS-20004 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
HR020602 injection | Phase 2 | Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol) | - | - |
SS109 | Phase 2 | Male | - | - |
HS-10365 capsules | Phase 2 | Nonsmall Cell Lung Cancer | - | - |
Pegylated rhG-CSF 100μg/kg | Phase 2 | Breast Cancer | - | - |
HR19042 Capsules | Phase 2 | Autoimmune Hepatitis | - | - |
HRS-9190 | Phase 2 | Neuromuscular Blockade | - | - |
SHR0302Base gel | Phase 2 | Vitiligo | - | - |
Abiraterone Acetate Tablets (I) | Phase 2 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | - | - |
HRS-6209 in Combination with Fulvestrant | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
HRS-1167 tablets | Phase 2 | Prostate Cancer | - | - |
HRS-4642 | Phase 2 | Advanced Solid Tumors | - | - |
HRS4800 tablets | Phase 2 | Pain | - | - |
HS-20094 | Phase 2 | Type 2 Diabetes | - | - |
SHR7280 | Phase 2 | Endometriosis | - | - |
SHR-A1904 | Phase 2 | Advanced Solid Tumors | - | - |
50 mg SP2086 | Phase 2 | Type 2 Diabetes | - | - |
SHR-1703 | Phase 2 | Asthma With Eosinophilic Phenotype | - | - |
HRS-6209 Capsules | Phase 2 | Breast Cancer | - | - |
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin | Phase 2 | Lung Cancer | - | - |
HRS-6768 | Phase 2 | Advanced Solid Tumors | - | - |
SHR- A1811 | Phase 2 | Gynaecological Malignancies | - | - |
HRS-5041 tablets | Phase 2 | Prostate Cancer | - | - |
HRS-6213 | Phase 2 | Patients With Solid Tumors | - | - |
SHR2554; SHR-A2102 | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | - | - |
Fluzoparib+Apatinib | Phase 2 | Relapsed Ovarian Cancer | - | - |
FH-006 | Phase 2 | Malignant Solid Tumor | - | - |
SHR 1210+apatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
Meropenem | Phase 2 | Hospital-acquired Bacterial Pneumonia (HABP) | - | - |
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection) | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |
SHR-3167 | Phase 2 | Type 2 Diabetes | - | - |
SHR-A1811 combined with Pyrotinib. | Phase 2 | HER2-expressing Advanced Solid Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 133 drug candidates in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JNGHF) pipeline across Phase 3, Phase 2. Its lead program is HRS-4357 injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's next FDA catalyst?→
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JNGHF) next tracked catalyst is a Phase 2 expected June 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JNGHF biotech catalysts?→
Add JNGHF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.